The nine-valent cervical cancer vaccine is suitable for women aged 16-26 years old and is designed to prevent vulvar, vaginal, anal, genital warts, precancerous or atypical lesions caused by HPV, or human papillomavirus. If women who are already sexually active or infected with HPV are vaccinated with the nine-valent cervical cancer vaccine, the immune effect produced later in the vaccination will be relatively reduced. The nine-valent cervical cancer vaccine requires a total of three inoculations, with the three inoculations completed within six months. If an unplanned pregnancy occurs during the inoculation process, it is recommended to stop the inoculation and consider continuing the pregnancy, which can be done during menstruation. The nine-valent cervical cancer vaccine mainly targets HPV virus types 6, 11, 16, 18, 31, 33, 45, 52 and 56 and can prevent more than 90% of cervical cancers. Cervical cancer is a common and frequent malignant tumor in gynecology. With the widespread implementation of cervical cancer screening, the incidence of cervical cancer is on a decreasing trend. With the popularization of cervical cancer vaccine, it is even more beneficial to reduce the incidence of cervical cancer. Women are recommended to get HPV vaccine and have regular cervical cancer screenings to care for their health.